PharmaTher and Sairiyo Discover Cepharanthine's Potential
![PharmaTher and Sairiyo Discover Cepharanthine's Potential](https://investorshangout.com/images/blog/investors-hangout-newswire.jpg)
PharmaTher’s Sairiyo Therapeutics Announces Independent Screening
PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announces that Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is forty-nine percent (49%) owned by PharmaTher and fifty-one percent (51%) owned by PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF), announced that an independent screening of drugs for monkeypox (“Mpox”) highlighted cepharanthine’s potential to bind to the virus’s proteins. The letter to the editor titled, "Highly accurate protein structure prediction and drug screen of monkeypox virus proteome", is non peer reviewed and published in Journal of Infection.
Understanding Monkeypox Proteins
Understanding Mpox (monkeypox) proteins key to the function of the virus is limited. Identification of potential drugs/molecules that interact with Mpox proteins may help with treatment of Mpox virus infection. In a study by Yang et al, 10 target proteins from the Mpox virus were selected due to their potential to be involved in essential functions and their potential to interact with other molecules. In the published research study aimed at screening drugs for Mpox, cepharanthine displayed significant binding affinities to all ten target proteins of Mpox. More specifically, cepharanthine showed high binding affinities to 4 of the predicted Mpox proteins (I1L, VITF3L, A42R, and E8L). This predicted interaction may help enhance understanding of key mechanisms of viral entry and replication for potential treatments of Mpox infection, cepharanthine.
Clinical Study Approval Announcement
Sairiyo received approval by the Australian Human Research Ethics Committee to initiate a first-in-human Phase 1 clinical study with PD-001. Sairiyo is targeting PD-001 as a potential treatment for Medical Countermeasures. PD-001 was previously awarded a $3.4 million contract from the Defense Threat Reduction Agency (DTRA) for the Ebola virus.
Cepharanthine Overview
The Company would like to make it clear that it is not making any express or implied claims that its product (cepharanthine) has the ability to treat, eliminate, or cure Monkeypox (Mpox) and/or other infectious diseases at this time.
About PD-001 (Enteric-coated Oral Cepharanthine)
Cepharanthine is a natural product and an approved drug used for more than 70 years in Japan to successfully treat a variety of acute and chronic diseases. In clinical research, cepharanthine has been shown to exhibit multiple pharmacological properties including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic effects. However, historically, cepharanthine's low oral bioavailability has represented a major obstacle to realizing its full clinical potential.
Improved Formulation
Compared to generic cepharanthine, PD-001 has been shown in rodent and non-rodent models to possess markedly improved oral bioavailability (more easily absorbed). These findings support the development of an orally administered formulation, and in so doing, removes the undesirable requirement for frequent intravenous dosing to maintain therapeutic levels of drug in circulation. Sairiyo endeavours to develop an efficacious oral therapeutic to potentially improve outcomes for infectious disease and oncology applications.
Patent Protection
PD-001 is protected by US Patent US10576077, with a patent expiration date of March 23, 2036.
About Sairiyo Therapeutics Inc.
Sairiyo Therapeutics Inc., which is owned by PharmDrug Inc. (51%) and PharmaTher (49%), is focused on advancing the clinical development of an improved and patented enteric-coated orally bioavailable formulation of cepharanthine (PD-001) as a potential treatment for Medical Countermeasures and oncology.
About PharmaTher Holdings Ltd.
PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on the development and commercialization of KETARX™ (Ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. PharmaTher owns 49% of Sairiyo Therapeutics Inc., which focuses on advancing the clinical development of an improved and patented enteric-coated orally bioavailable formulation of cepharanthine (PD-001) for medical countermeasures and cancer. Learn more at PharmaTher.com.
For more information about PharmaTher, please contact:
Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com
Frequently Asked Questions
What is cepharanthine?
Cepharanthine is a natural compound with various pharmacological effects, historically used in Japan for treating several diseases.
What is the significance of Sairiyo's discoveries?
Sairiyo's research identifies the potential of cepharanthine to bind to monkeypox proteins, which could aid in developing treatments.
How has cepharanthine been tested in research?
Research has shown that cepharanthine exhibits significant binding affinities to target proteins associated with the Mpox virus.
What clinical studies are currently underway?
Sairiyo is initiating a Phase 1 clinical study for PD-001 as a potential treatment for medical countermeasures.
How does PD-001 differ from regular cepharanthine?
PD-001 has improved oral bioavailability compared to generic cepharanthine, enhancing its therapeutic potential.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/